Remove 2030 Remove Planning Remove Portfolio Remove Taxes
article thumbnail

Can MRPL pump up its profit like it did before? A look into its future plans

Trade Brains

until 2030. While looking at the net profit MRPL profit decreased by 10.23% because of increased payment of taxes so it came down from 2958.25 In June 07 2023, Sanjay Varma the managing director of MRPL said they are planning to construct a new petrochemical plant in Karnataka. crore rupees to 2655.41 crore rupees.

article thumbnail

Fundamental Analysis Of Servotech Power Systems – Future Plans & More

Trade Brains

The article concludes with a highlight of future plans and a summary. Solar Industry The solar power industry in India is rapidly expanding, with an expected market value of around $238 billion by 2030, driven by a remarkable 40% CAGR between 2023 and 2032. from 2023 to 2030. India is set to generate 79.07 Crores in FY23.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Fundamental Analysis of Mazagon Dock – Future Plans & More

Trade Brains

A highlight of the future plans & recent developments and a summary conclude the article at the end. Thus, going forward indigenization plan as part of the “Atmanirbhar Bharat” vision, higher capital defence expenditure and maritime trade growth will drive the shipbuilding and repair industry in India. lakh crore in 2023-24.

article thumbnail

Fundamental Analysis Of Aurobindo Pharma – Future Plans & More

Trade Brains

The article concludes with a highlight of future plans and a summary. India’s pharmaceutical sector is projected to be worth US$65 billion by 2024 and US$130 billion by 2030. The net profit margins of the company were further impacted due to factors higher finance costs and tax rates. Ramprasad Reddy, and Mr. K.

article thumbnail

Best Cancer Pharma stock in India 2024 to keep an eye on!

Trade Brains

Beta drugs’ oncology portfolio shows a shift towards supportive care and hemat products as the percentage of Hemat and supportive care went up from 11% and 16% respectively in FY 21-22 to 19% and 13% in FY 23-24. Future Outlook: Beta Drugs plans to broaden its product portfolio as it is planning to launch 25 new products by 2026.

article thumbnail

Fundamental Analysis Of KEC International – Future Plans & More

Trade Brains

The article concludes with a highlight of plans and a summary. trillion by 2030. It is supported by a 33% increase in planned capital expenditure by the government. Future Plans Of KEC International So far we looked at the previous fiscals’ data for our fundamental analysis of KEC International. of the global GDP.

article thumbnail

Fundamental Analysis Of Neuland Laboratories – Future Plans & More

Trade Brains

The article concludes with a highlight of future plans and a summary. from 2020 to 2030. The table below shows the total income and net profit of Neuland Laboratories for 5 financial years: Year Total income (₹ In crores) Profit after tax (₹ In crores) 2023 1,200.95 from 2016 to 2019. It is projected to grow at a CAGR of 12.3%